Connect Biopharma Holdings Limited Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Connect Biopharma Holdings Limited (CNTB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 15.46 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Connect Biopharma Holdings Limited antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 15.77M shares, a 14.22% increase year-over-year.
- Connect Biopharma Holdings Limited antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 13.80M shares, a 75.32% increase year-over-year.
- Connect Biopharma Holdings Limited antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.87M shares.
- Connect Biopharma Holdings Limited antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 15.75M shares, a 6.95% increase from fiscal 2024.
- Connect Biopharma Holdings Limited antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 14.73M shares, a 125.40% increase from fiscal 2023.
- Connect Biopharma Holdings Limited antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.54M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 15.46M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 15.77M shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 15.75M shares 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 14.23M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 14.64M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 13.80M shares 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 14.73M shares 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 13.30M shares 10-Q · filed 2025-11-12 | |||
| 2024-03-31 | 7.87M shares 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 6.54M shares 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |